Ofev 150 — Nintedanib 150 mg (60 Capsules)
Ofev 150 mg (Nintedanib) is an innovative targeted medication designed for the treatment of severe fibrosing lung diseases. The active substance, nintedanib, is a potent tyrosine kinase inhibitor. It blocks the receptors responsible for the proliferation of connective tissue in the lungs, thereby slowing down the "scarring" process (fibrosis). The 150 mg dosage is the primary therapeutic dose, providing maximum control over disease progression.
Manufacturer: Boehringer Ingelheim, Germany. Ofev 150 significantly reduces the rate of decline in forced vital capacity and decreases the risk of acute pulmonary exacerbations, which can be life-threatening. The drug allows for slowing the disease progression and helps patients maintain physical activity longer.
Key Features:
- ✅ Maximum Concentration: The 150 mg dosage provides optimal anti-fibrotic action according to international protocols.
- ✅ Slowing Fibrosis: Direct impact on growth factors (VEGFR, FGFR, PDGFR) that cause pathological changes in the lungs.
- ✅ Clinical Standard: The primary medication for the therapy of idiopathic pulmonary fibrosis worldwide.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 04.06.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!